{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.8","upperLimit":"20.0","value":"17.2"},{"groupId":"OG001","lowerLimit":"12.0","upperLimit":"19.0","value":"14.6"},{"groupId":"OG002","lowerLimit":"6.8","upperLimit":"18.6","value":"13.9"},{"groupId":"OG003","lowerLimit":"3.5","upperLimit":"26.7","value":"11.1"},{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"8.9","upperLimit":"NA","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is Overall Survival (OS). OS is defined as the date from first dose of rucaparib to the date of death due to any cause, +1 day.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"MEDIAN","populationDescription":"Safety Population - The safety population consists of all patients who received at least 1 dose of protocol-specified treatment.","reportingStatus":"POSTED","timeFrame":"From date of first dose until event, loss to follow-up, withdrawal of consent, or study closure: an overall median of approximately 33.1 months","title":"Overall Survival (OS) by Gene","type":"SECONDARY","unitOfMeasure":"months"}